Current treatment options in infectious diseases最新文献_第6页

Using Technology to Enhance Antimicrobial Stewardship Impact in the Acute Care Setting 利用技术提高抗菌药物管理在急症护理环境中的影响

Current treatment options in infectious diseases Pub Date : 2020-04-23 DOI: 10.1007/s40506-020-00218-5

Kelsie Cowman, Victor Chen, Yi Guo, Priya Nori

引用次数: 5

Improving Diagnostic and Laboratory Capacity Helps in Control of Infection: an Indian Perspective 提高诊断和实验室能力有助于控制感染:一个印度的观点

Current treatment options in infectious diseases Pub Date : 2020-03-28 DOI: 10.1007/s40506-020-00215-8

S. Bhattacharya

引用次数: 3

Endemic Fungi in Transplant and Immunocompromised Hosts: Epidemiology, Diagnosis, Treatment, and Prevention 移植和免疫受损宿主中的地方性真菌：流行病学、诊断、治疗和预防

Current treatment options in infectious diseases Pub Date : 2020-02-26 DOI: 10.1007/s40506-020-00212-x

Esther Benamu, C. Hogan, C. Gomez

引用次数: 2

What Is New in Candida Infections? T2Candida, Antifungal Stewardship, and Candida auris 念珠菌感染有什么新进展?2 .念珠菌、抗真菌管理和耳念珠菌

Current treatment options in infectious diseases Pub Date : 2020-02-05 DOI: 10.1007/s40506-020-00209-6

C. Clancy, M. Nguyen

引用次数: 0

Prophylaxis and Treatment of Invasive Aspergillosis: Who and How of Prophylaxis, Treatment, and New Therapies 侵袭性曲霉菌病的预防和治疗：谁以及如何预防、治疗和新疗法

Current treatment options in infectious diseases Pub Date : 2020-01-30 DOI: 10.1007/s40506-020-00213-w

P. Vergidis, D. Denning

引用次数: 1

Cryptococcal Immune Reconstitution Inflammatory Syndrome: a Paradoxical Response to a Complex Organism 隐球菌免疫重建炎症综合征:对复杂生物体的矛盾反应

Current treatment options in infectious diseases Pub Date : 2020-01-24 DOI: 10.1007/s40506-020-00210-z

I. Mohamedy, G. Forrest

引用次数: 0

Up-to-Date Infection Control Practices for Febrile Neutropenic Patients 发热性中性粒细胞减少症患者最新感染控制措施

Current treatment options in infectious diseases Pub Date : 2020-01-24 DOI: 10.1007/s40506-020-00214-9

H. Morales, P. Puerta-Alcalde, Gemma Sanjuan-Gomez, E. Moreno-García, Mariana Chumbita, Nicole García-Poutón, Á. Soriano, C. García-Vidal

引用次数: 2

Japanese Encephalitis Vaccines. 日本脑炎疫苗。

Current treatment options in infectious diseases Pub Date : 2020-01-01 Epub Date: 2020-11-12 DOI: 10.1007/s40506-020-00242-5

Vijaya Satchidanandam

{"title":"Japanese Encephalitis Vaccines.","authors":"Vijaya Satchidanandam","doi":"10.1007/s40506-020-00242-5","DOIUrl":"https://doi.org/10.1007/s40506-020-00242-5","url":null,"abstract":"Purpose of review: As an eminently vaccine-preventable disease, encephalitis caused by Japanese encephalitis virus (JEV) has attracted an unusually high degree of attention from those seeking to develop viral vaccines. Since the 1950s, all types of JEV vaccines including inactivated, recombinant and live attenuated ones have been licensed. As an example of an extremely successful endeavour, the time is ripe for reviewing the development of JEV vaccines and probing the reasons behind their uniform success.Recent findings: Vaccines against JEV have come a long way since the first licensing in the mid-1950s of the mouse brain-grown-inactivated virus preparations, to the present day live-attenuated virus vaccines. A survey of the various inactivated and live vaccines developed against JEV provides a striking insight into the impressive safety and efficacy of all the vaccines available to prevent encephalitis from JEV. This review juxtaposes studies to understand naturally acquired immunity against JEV that have mostly been published post-2000, compares these with those elicited by vaccines and highlights the paucity of data on cell-mediated immune responses elicited by JEV vaccines.Summary: This article not only seeks to make available the immense salient literature on this endeavour in one collection, but also queries the basis for the remarkable success of JEV vaccines, not least of which may be the ease of protecting against encephalitis caused by JEV. To conclude, the true test of the ingenuity of those dedicated to the pursuit of viral vaccines would be success against viral diseases such as HIV-AIDS and dengue that pose a far greater challenge to scientists.","PeriodicalId":72759,"journal":{"name":"Current treatment options in infectious diseases","volume":"12 4","pages":"375-386"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40506-020-00242-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38613125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 18

Using Artificial Intelligence in Infection Prevention. 人工智能在感染预防中的应用

Current treatment options in infectious diseases Pub Date : 2020-01-01 Epub Date: 2020-03-19 DOI: 10.1007/s40506-020-00216-7

Fidelma Fitzpatrick, Aaron Doherty, Gerard Lacey

{"title":"Using Artificial Intelligence in Infection Prevention.","authors":"Fidelma Fitzpatrick, Aaron Doherty, Gerard Lacey","doi":"10.1007/s40506-020-00216-7","DOIUrl":"https://doi.org/10.1007/s40506-020-00216-7","url":null,"abstract":"Purpose of review: Artificial intelligence (AI) offers huge potential in infection prevention and control (IPC). We explore its potential IPC benefits in epidemiology, laboratory infection diagnosis, and hand hygiene.Recent findings: AI has the potential to detect transmission events during outbreaks or predict high-risk patients, enabling development of tailored IPC interventions. AI offers opportunities to enhance diagnostics with objective pattern recognition, standardize the diagnosis of infections with IPC implications, and facilitate the dissemination of IPC expertise. AI hand hygiene applications can deliver behavior change, though it requires further evaluation in different clinical settings. However, staff can become dependent on automatic reminders, and performance returns to baseline if feedback is removed.Summary: Advantages for IPC include speed, consistency, and capability of handling infinitely large datasets. However, many challenges remain; improving the availability of high-quality representative datasets and consideration of biases within preexisting databases are important challenges for future developments. AI in itself will not improve IPC; this requires culture and behavior change. Most studies to date assess performance retrospectively so there is a need for prospective evaluation in the real-life, often chaotic, clinical setting. Close collaboration with IPC experts to interpret outputs and ensure clinical relevance is essential.","PeriodicalId":72759,"journal":{"name":"Current treatment options in infectious diseases","volume":"12 2","pages":"135-144"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40506-020-00216-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37776485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 34

Hantavirus Infections-Treatment and Prevention. 汉坦病毒感染-治疗和预防。

Current treatment options in infectious diseases Pub Date : 2020-01-01 Epub Date: 2020-10-29 DOI: 10.1007/s40506-020-00236-3

Kalpa Dheerasekara, Saranga Sumathipala, Rohitha Muthugala

{"title":"Hantavirus Infections-Treatment and Prevention.","authors":"Kalpa Dheerasekara, Saranga Sumathipala, Rohitha Muthugala","doi":"10.1007/s40506-020-00236-3","DOIUrl":"https://doi.org/10.1007/s40506-020-00236-3","url":null,"abstract":"Purpose of review: Hantavirus infection is an emerging zoonosis and there are two main clinical presentations, hemorrhagic fever with renal syndrome (HFRS) and Hantavirus pulmonary syndrome (HPS). Although Hantavirus infections have a worldwide distribution with a high mortality rate, a safe and effective vaccine or an antiviral drug against the Hantavirus disease is yet to be available. This review summarizes all the efforts undertaken to develop medical countermeasures in vitro, in vivo, and human clinical trials against Hantavirus infections.Recent findings: Multiple antivirals are shown to be effective with limited evidence and recent studies on immunotherapy were not very conclusive. There are multiple vaccine candidates with evidence of conferring long protective immunity against Hantaviruses. Some of these had been already trialed on humans.Summary: At present, severe HPS or HFRS case management is purely based on supportive treatments, often in an intensive care unit. Rodent control and public health education and promotion play a major role in preventing Hantavirus infection.","PeriodicalId":72759,"journal":{"name":"Current treatment options in infectious diseases","volume":"12 4","pages":"410-421"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40506-020-00236-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38562819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 20